ECI Biotech Inc. Product Pipeline Analysis

SUMMARY

ECI Biotech Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a ECI Biotech Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List Of Tables 5
1.2 List of Figures 6
2 Company Overview 7
2.1 Key Information 7
2.2 Industry Outlook -- Storage 7
2.3 Industry Outlook -- Patient Monitoring 7
2.4 Industry Outlook -- In Vitro Diagnostics 8
3 Major Products and Services 9
3.1 Overview 9
4 Competitors 10
5 Key Employees 11
6 Locations And Subsidiaries 12
6.1 Head Office 12
7 Recent Developments 13
7.1 Product News 13
7.1.1 Aug 01, 2008: ECI Biotech Bacterial Test Awarded $949,000 Grant 13
7.1.2 Feb 20, 2008: SBIR Funding From The National Institute Of Allergy And Infectious Diseases At NIH 13
7.1.3 Apr 02, 2007: ECI Biotech Receives $208,311 in SBIR Funding 13
8 ECI Biotech Inc. Pipeline Products 14
8.1 ECI Biotech Inc. Product Pipeline Analysis 14
8.1.1 ECI Biotech Inc. Pipeline Products By Equipment Type 14
8.1.2 ECI Biotech Inc. Pipeline Products By Development Stage 15
8.1.3 ECI Biotech Inc. Pipeline Products By Therapy Area 15
8.1.4 ECI Biotech Inc. Pipeline Products By News Summary 16
8.2 ExpressDetect Test 16
8.2.1 Product Description 16
8.2.2 Product Status 16
8.2.3 Product Milestone 17
8.3 ExpressDetect Test 17
8.3.1 Product Description 17
8.3.2 Product Status 18
8.3.3 Product Milestone 18
8.4 Rapid test for vaginal yeast infections 18
8.4.1 Product Description 18
8.4.2 Product Status 19
8.4.3 Product Milestone 19
9 Appendix 20
9.1 Methodology 20
9.1.1 Coverage 20
9.1.2 Secondary Research 21
9.1.3 Primary Research 21
9.1.4 Expert Panel Validation 22
9.2 Contact Us 22
9.3 About Global Markets Direct 22
9.4 Disclaimer 22

1.1 List of Tables
Table 1: ECI Biotech Inc.,Key Facts 7
Table 2: ECI Biotech Inc., Key Employees, 11
Table 3: ECI Biotech Inc. Pipeline Products by Equipment Type 14
Table 4: ECI Biotech Inc. Pipeline Products By Development Stage 15
Table 5: ECI Biotech Inc. Pipeline Products By Therapy Area 15
Table 6: ECI Biotech Inc. Pipeline Products By News Summaries 16

1.2 List of Figures
Figure 1: ECI Biotech Inc. Pipeline Products By Development Stage 15
Figure 2: Global Markets Direct Methodology 20